Proactive Investors - Run By Investors For Investors

Diurnal shares rocket after hormonal diseases specialist granted second US patent for cortisol replacement product, Chronocort

Diurnal said the patent provides in-market protection until 2033 and is in addition to the already granted pharmaceutical composition of matter patent, which provides in-market protection until 2034
Patent news
Martin Whitaker, Diurnal’s chief executive officer commented: "This second Chronocort patent provides additional in-market protection in the US, which remains a key target market"

Diurnal Group PLC (LON:DNL) rocketed nearly 200% higher on Thursday after the hormonal diseases specialist announced the grant of a second US patent for Chronocort, a cortisol replacement product for the life-long treatment of congenital adrenal insufficiency and adrenal insufficiency.

The AIM-listed group said US 10,166,194, entitled "Hydrocortisone Controlled Release Formulation", is a patent claiming a method of treatment for adrenal dysfunction, including the diseases congenital adrenal hyperplasia (CAH) and adrenal insufficiency (AI), that delivers hydrocortisone in accordance with a circadian rhythm.

READ: Diurnal Group’s market value halved as lead drug fails late-stage study

Diurnal said the patent provides in-market protection until 2033 and is in addition to the already granted pharmaceutical composition of matter patent US 9,750,704, which provides in-market protection until 2034.

Diurnal said the United States was expected to be a major territory for sales of Chronocort, with CAH and AI collectively estimated to affect 140,000 adult patients and have an addressable market of around US$1bn.

Martin Whitaker, Diurnal’s chief executive officer commented: "This second Chronocort patent provides additional in-market protection in the US, which remains a key target market for Diurnal, in addition to the potential for market exclusivity provided by the award of Orphan Drug Designation for both CAH and AI.”

He added: “With patents now extending protection in the US for both Chronocort and our paediatric product Alkindi to 2034, we are confident that, if approved, these products will enjoy a long period of exclusivity in the US market and provide the potential for lifelong treatment of patients with CAH and AI."

Shares surge – but from low base

In afternoon trading, Diurnal was easily the London market’s top gainer, up 195% today to 63.50p, although the shares were trading at around 178p a year ago.

Diurnal’s share price more than halved in October after the Chronocort drug failed in a late-stage clinical trial.

Whitaker said then: “We will now analyse the full data set from this trial, along with interim data from the ongoing Chronocort long-term dosing study, to determine next steps in Chronocort development, and discuss these with the regulatory authorities.”

He added: “We remain confident that Chronocort will be a valuable treatment option for CAH patients.”

View full DNL profile View Profile

Diurnal Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
scientist in lab
December 20 2018
Data from Midatech's MTD201 drug has validated the company's Q-Sphera sustained release technology, and other, bigger players are starting to sit up and take note
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use